acute osteomyelitis, septic arthritis
Conditions
Interventions
None listed
Sponsors
Tokyo Metropolitan Chidren's Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1 Diagnosed with acute osteomyelitis or septic arthritis at a single site based on fever, local symptoms, and imaging findings, or diagnosed with both acute osteomyelitis and septic arthritis. 2 Aged over 1 month and under 19 years old. 3 Those who showed treatment responsiveness* to initial treatment within 5 days after treatment initiation**. 4 Cases with no positive blood culture beyond 2 days after treatment initiation**. 5 Microorganisms identified from blood, joint fluid, and pus, with susceptibility. 6 Able to take medication orally or through tube feeding, and the drug can be absorbed from the gastrointestinal tract. *Treatment responsiveness: Determined when fever resolves and local redness, swelling, and pain improve compared to before treatment initiation. **Treatment initiation: Day 1 is considered as the day of the second administration of initial antimicrobial therapy.
Exclusion criteria
Exclusion criteria: 1 Those with causative microorganisms resistant to MRSA, PRSP, or other drug-resistant or acid-fast bacteria. 2 Those diagnosed as chronic osteomyelitis (with symptoms present for over 2 weeks before treatment initiation, etc.). 3 Those diagnosed with congenital or acquired immunodeficiency syndrome. 4 Cases of arthritis or osteomyelitis following trauma, surgery, or foreign body placement. 5 Cases of non-hematogenous arthritis or osteomyelitis due to direct extension from primary infectious foci. 6 Those who opted not to disclose information about this study and indicated refusal. 7 Others deemed unsuitable as subjects by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The cure rate at 6 months from the start of treatment, meaning the absence of symptoms and signs of acute osteomyelitis and septic arthritis, and no requirement of additional antimicrobial therapy due to recurrence. | — |
Countries
Japan
Contacts
Public ContactAki Miyashita
Tokyo Metropolitan Children's medical center Division of infectious disease
Outcome results
None listed